Stocks · News reference
Oncopeptides AB announced its third-quarter 2026 financial results, highlighting a 41% year-over-year increase in sales and a 98% gross margin for the first nine months of the year.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Onco-Innovations Limited has entered into a termination agreement with Sorbie Bornholm LP and Sorbie Investments LLP to end their performance-based funding arrangement.
The European Commission has formally approved a Type II variation for Oncopeptides' Pepaxti, expanding its use to adult patients with multiple myeloma who have received at least two prior lines of therapy.
Filed: 2026-11-09 AccNo: 0001213900-26-117223 Size: 211 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
Onconetix, Inc. entered into a first amendment to its stock-for-stock merger agreement with Realbotix, as disclosed in an SEC filing dated November 4, 2026.
Onconetix, Inc. issued a summary regarding the launch of the Echo humanoid robot platform by Realbotix, the target of its pending acquisition.